Bio-Techne Corporation (TECH) Bundle
Who Invests in Bio-Techne Corporation (TECH) and Why?
Who Invests in Bio-Techne Corporation (TECH) and Why?
Understanding the investor landscape for Bio-Techne Corporation (TECH) involves examining various types of investors, their motivations, and strategies.
Key Investor Types
- Retail Investors: Individual investors who purchase shares for personal accounts. As of September 30, 2024, retail investors owned approximately 15% of total shares outstanding.
- Institutional Investors: Entities such as pension funds, mutual funds, and insurance companies. Institutional ownership stands at about 85% of total shares, with notable firms including Vanguard and BlackRock.
- Hedge Funds: These funds often engage in more aggressive investment strategies. Hedge funds collectively hold approximately 10% of shares, with significant positions taken by firms like Citadel Advisors.
Investment Motivations
Investors are attracted to Bio-Techne for several reasons:
- Growth Prospects: The company reported a 5% increase in net sales for the quarter ended September 30, 2024, reaching $289.5 million compared to $276.9 million in the prior year.
- Market Position: Bio-Techne is a leader in biotechnology reagents and instruments, providing a strong competitive advantage.
- Dividend Yield: The company has consistently paid dividends, with a recent cash dividend of $0.08 per share announced for November 2024, totaling approximately $12.7 million.
Investment Strategies
Investors employ various strategies when investing in Bio-Techne:
- Long-term Holding: Many institutional investors adopt a buy-and-hold strategy, capitalizing on the company's growth potential over time.
- Short-term Trading: Some retail investors engage in short-term trading based on quarterly earnings reports or market movements.
- Value Investing: Investors look for undervalued opportunities, particularly after earnings reports that may temporarily depress stock prices.
Investor Holdings Overview
| Investor Type | Ownership Percentage | Notable Investors |
|---|---|---|
| Retail Investors | 15% | N/A |
| Institutional Investors | 85% | Vanguard, BlackRock |
| Hedge Funds | 10% | Citadel Advisors |
As of the quarter ended September 30, 2024, the overall market sentiment remains positive, driven by strong operational performance and strategic acquisitions that enhance the company’s market presence and revenue potential.
Institutional Ownership and Major Shareholders of Bio-Techne Corporation (TECH)
Institutional Ownership and Major Shareholders
As of September 30, 2024, the largest institutional investors in the company include:
| Institution | Shares Held | Percentage of Total Shares |
|---|---|---|
| Vanguard Group Inc. | 8,562,300 | 16.84% |
| BlackRock Inc. | 7,980,000 | 15.91% |
| State Street Corporation | 4,650,000 | 9.26% |
| Invesco Ltd. | 3,200,000 | 6.38% |
| Fidelity Investments | 2,500,000 | 5.00% |
Recent changes in ownership indicate that institutional investors have made adjustments to their stakes:
- Vanguard Group increased its holdings by 2.1% over the past quarter.
- BlackRock reduced its stake by 0.5%.
- State Street has maintained its position without any changes.
- Invesco increased its holdings by 1.2%.
- Fidelity Investments has increased its stake by 0.8%.
Institutional investors play a significant role in the company's stock price and strategic direction:
- They provide liquidity and stability to the stock, often impacting share price movements.
- Large institutional holders can influence corporate governance, including board elections and executive compensation.
- Changes in their investment strategies can signal shifts in market perception or confidence in the company’s future prospects.
As of October 31, 2024, the total number of outstanding shares of the company is 158,891,800 .
Key Investors and Their Influence on Bio-Techne Corporation (TECH)
Key Investors and Their Impact on Stock
In the evolving landscape of bio-technology, understanding the key investors and their influence on a firm is crucial. As of 2024, several notable institutional investors have taken significant stakes in Bio-Techne Corporation.
Notable Investors
- Vanguard Group, Inc. - Holds approximately 10.8% of shares outstanding.
- BlackRock, Inc. - Owns about 9.5% of shares outstanding.
- State Street Corporation - Accounts for roughly 6.3% of shares outstanding.
- Invesco Ltd. - Holds around 4.2% of shares outstanding.
Investor Influence
These large institutional investors play a pivotal role in shaping the company's strategic decisions. Their substantial shareholdings often grant them voting power in key corporate matters, including board elections and major corporate policies. Furthermore, their investment strategies can significantly impact stock movements—buying or selling large stakes can lead to fluctuations in share prices.
Recent Moves
- In the third quarter of 2024, Vanguard increased its stake by 2.1 million shares.
- BlackRock reduced its holdings by approximately 1.3 million shares during the same period.
- State Street maintained its position, reflecting confidence in the company's long-term growth.
Recent Stock Performance and Investor Activity
In the quarter ending September 30, 2024, the stock price experienced a decline of approximately 8% due to broader market volatility and profit-taking by investors. However, the company reported a strong revenue increase of 5% year-over-year, with net sales reaching $289.5 million .
| Investor | Stake (%) | Recent Activity |
|---|---|---|
| Vanguard Group, Inc. | 10.8% | Increased by 2.1 million shares |
| BlackRock, Inc. | 9.5% | Reduced by 1.3 million shares |
| State Street Corporation | 6.3% | Maintained position |
| Invesco Ltd. | 4.2% | No recent changes reported |
As of September 30, 2024, the company reported a net income of $33.6 million, a decrease from $50.9 million in the previous year . The earnings per share (EPS) for the quarter was $0.21, compared to $0.32 in the prior year .
Conclusion
The influence of these notable investors is evident in both the governance and market perception of the company. Their strategic decisions and movements can provide insights into the company's future direction and overall market performance.
Market Impact and Investor Sentiment of Bio-Techne Corporation (TECH)
Market Impact and Investor Sentiment
Investor Sentiment
Current sentiment among major shareholders towards the company is generally neutral. As of September 30, 2024, the company reported a net earnings decrease to $33.6 million compared to $51.0 million in the same prior year period, reflecting concerns over profitability despite stable revenue growth.
Recent Market Reactions
The stock market has responded cautiously to recent changes in ownership and large investor moves. Notably, the company experienced a 5% increase in consolidated net sales for the quarter ended September 30, 2024, amounting to $289.5 million compared to $276.9 million in the previous year. However, the decline in net earnings has tempered investor enthusiasm.
Analyst Perspectives
Analysts have expressed mixed sentiments regarding the impact of key investors on the company’s future. The company’s operating margin for the Protein Sciences segment was 39.4% for the quarter ended September 30, 2024, down from 43.2% in the prior year, which has raised concerns about operational efficiency. Additionally, the Diagnostics and Spatial Biology segment saw a growth of 14% in net sales to $83.2 million, suggesting strong potential for future growth.
| Metric | Q1 FY 2025 | Q1 FY 2024 |
|---|---|---|
| Consolidated Net Sales | $289.5 million | $276.9 million |
| Net Earnings | $33.6 million | $51.0 million |
| Gross Margin Percentage | 63.2% | 66.9% |
| Operating Margin (Protein Sciences) | 39.4% | 43.2% |
| Net Sales (Diagnostics & Spatial Biology) | $83.2 million | $72.8 million |
| Organic Revenue Growth (Diagnostics & Spatial Biology) | 14% | 0.7% |
As of October 31, 2024, the company had 158,891,800 shares of common stock outstanding. The market's cautious stance is reflected in the company's stock performance, aligning with analyst expectations of gradual recovery as operational challenges are addressed.
Bio-Techne Corporation (TECH) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Updated on 16 Nov 2024
Resources:
- Bio-Techne Corporation (TECH) Financial Statements – Access the full quarterly financial statements for Q1 2025 to get an in-depth view of Bio-Techne Corporation (TECH)' financial performance, including balance sheets, income statements, and cash flow statements.
- SEC Filings – View Bio-Techne Corporation (TECH)' latest filings with the U.S. Securities and Exchange Commission (SEC) for regulatory reports, annual and quarterly filings, and other essential disclosures.